Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| Inhibitor Therapeutics, Inc.INTI · Entity 7783 | Director | May 04, 2026 | August 04, 2026 |
| MIRA PHARMACEUTICALS, INC.MIRA · Entity 7362 | Chief Financial Officer | December 09, 2024 | December 10, 2024 |
| Telomir Pharmaceuticals, Inc.TELO · Entity 6962 | Chief Financial Officer | August 27, 2024 | September 04, 2024 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
Inhibitor Therapeutics, Inc.
Report date May 04, 2026 · Filed August 04, 2026
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,221,271 |
Reported balance
After 2026-05-04 transaction · row 1
1 source rowRow 1 · 2026-05-04 · Grant · Acquired 50,000 · Balance 1,221,271 F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval. |
Filing footnotes · ownership attribution and instrument terms
F1: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval.
MIRA PHARMACEUTICALS, INC.
Report date December 09, 2024 · Filed December 10, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.19 · Expires 2034-12-09 | Direct | 150,000 |
Reported balance
After 2024-12-09 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-12-09 · Grant · Acquired 150,000 · Balance 150,000 F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024. F2: The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date. F3: Represents 150,000 stock options that were issued to the Reporting Person on December 6, 2024, that vest in equal halves on the six- and 12-month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $1.19 each. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024.
F2: The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date.
F3: Represents 150,000 stock options that were issued to the Reporting Person on December 6, 2024, that vest in equal halves on the six- and 12-month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $1.19 each.
Telomir Pharmaceuticals, Inc.
Report date August 27, 2024 · Filed September 04, 2024
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Incentive Stock Options (right to buy)SEC Table II · derivative / convertible security · Conversion / exercise price $5.02 · Expires 2034-08-27 | Direct | 200,000 |
Reported balance
After 2024-08-27 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2024-08-27 · Grant · Acquired 200,000 · Balance 200,000 F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. F2: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50,000 stock options of such grant shall vest, respectively, on each of February 26, 2025, August 26, 2025, February 26, 2026 and August 26, 2026. |
Filing footnotes · ownership attribution and instrument terms
F1: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024.
F2: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50,000 stock options of such grant shall vest, respectively, on each of February 26, 2025, August 26, 2025, February 26, 2026 and August 26, 2026.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| May 04, 2026 Filed Aug 4, 2026 16:19 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-26-035955 · ownership.xml · nonDerivative · entry 1 Yanez Michelle · CIK 0001958023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,221,271 F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2025 Equity Incentive Plan, subject to shareholder approval. Read SEC document |
| April 01, 2025 Filed Apr 7, 2025 21:25 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001641172-25-003033 · ownership.xml · nonDerivative · entry 1 Yanez Michelle · CIK 0001958023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 896,271 F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan. Read SEC document |
| December 09, 2024 Filed Dec 10, 2024 22:15 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.19 | $0.00 |
DisclosureSEC source: 0001493152-24-049508 · ownership.xml · derivative · entry 1 Yanez Michelle · CIK 0001958023 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 150,000 Underlying: Common Stock · 150,000 shares Expires 2034-12-09 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on December 6, 2024. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on December 6, 2024 (the "Grant Date"), pursuant to the Issuer's 2022 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50% of the options vest on the six-month anniversary of the grant date, and the remaining 50% vest on the one-year anniversary of the Grant Date. F3 · balance_after: Represents 150,000 stock options that were issued to the Reporting Person on December 6, 2024, that vest in equal halves on the six- and 12-month anniversaries of the grant date, pursuant to a grant under the Plan at an exercise price of $1.19 each. Read SEC document |
| December 02, 2024 Filed Feb 20, 2025 02:27 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GiftCommon Stock | 250,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-25-007626 · ownership.xml · nonDerivative · entry 1 Yanez Michelle · CIK 0001958023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 1,146,271 Read SEC document |
| August 27, 2024 Filed Sep 4, 2024 17:37 UTC | Telomir Pharmaceuticals, Inc. TELO · Entity 6962 | GrantIncentive Stock Options (right to buy) · Derivative | 200,000 | $0.00 Strike: $5.02 | $0.00 |
DisclosureSEC source: 0001493152-24-034962 · ownership.xml · derivative · entry 1 Yanez Michelle · CIK 0001958023 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 200,000 Underlying: Common Stock · 200,000 shares Expires 2034-08-27 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 26, 2024. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50,000 stock options of such grant shall vest, respectively, on each of February 26, 2025, August 26, 2025, February 26, 2026 and August 26, 2026. F2 · balance_after: The stock options were issued to the Reporting Person on August 26, 2024, pursuant to a grant under the Issuer's 2023 Omnibus Incentive Plan, as amended and restated (the "Plan"). 50,000 stock options of such grant shall vest, respectively, on each of February 26, 2025, August 26, 2025, February 26, 2026 and August 26, 2026. Read SEC document |
| April 01, 2024 Filed May 16, 2024 17:34 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | GrantCommon Stock | 50,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001493152-24-020171 · ownership.xml · nonDerivative · entry 1 Yanez Michelle · CIK 0001958023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 896,271 F1 · shares: Represents restricted common stock issued to the Reporting Person as compensation pursuant to the Issuer's 2014 Equity Incentive Plan. Read SEC document |
| March 26, 2024 Filed Mar 27, 2024 21:53 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantIncentive Stock Option (right to buy) · Derivative | 150,000 | $0.00 Strike: $1.15 | $0.00 |
DisclosureSEC source: 0001493152-24-011574 · ownership.xml · derivative · entry 1 Yanez Michelle · CIK 0001958023 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 57,799 Underlying: Common Stock · 150,000 shares Expires 2034-03-26 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on March 26, 2024. F2 · derivative.exercise_date: The options were granted under the Issuer's 2022 Amended and Restated Omnibus Incentive Plan (the "Plan") whereby 50% of such incentive options, or 75,000 options, will vest on the six month anniversary of the of the grant, or September 26, 2024, and the remaining 50% will vest on the first anniversary of the grant date, March 26, 2025. F3 · balance_after: Represents (i) 3,334 stock options that were issued to the Reporting Person under the Plan that became exercisable on June 15, 2022 at an exercise price of $5.00 (ii) 3,333 stock options that were issued to the Reporting Person under the Plan that became exercise on June 15, 2023 at an exercise price of $5.00 each, (iii) 15,566 stock options were issued to the Reporting Person on April 28, 2023, pursuant to a grant under the Issuer's Plan which vested in full on April 28, 2024 at an exercise price of $6.50 each, (iv) 15,566 stock options were issued to the Reporting Person on April 28, 2023, pursuant to a grant under the Issuer's Plan which will vest in full on April 28, 2024 at an exercise price of $6.50 each (v) 20,000 stock options were issued to the Reporting Person on August 17, 2023, pursuant to a grant under the Issuer's Plan which vested in full on August 17, 2023 at an exercise price of $6.50 each. Read SEC document |
| August 17, 2023 Filed Aug 21, 2023 22:00 UTC | MIRA PHARMACEUTICALS, INC. MIRA · Entity 7362 | GrantStock Options · Derivative | 20,000 | $0.00 Strike: $6.50 | $0.00 |
DisclosureSEC source: 0001493152-23-029735 · ownership.xml · derivative · entry 1 Yanez Michelle · CIK 0001958023 · CFO, Secretary and Treasurer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 20,000 Underlying: Common Stock · 20,000 shares Expires 2033-08-17 F1 · derivative.exercise_price: The exercise price of the stock options issued to the Reporting Person is equal to the closing price of the Issuer's common stock on August 17, 2023. F2 · derivative.exercise_date: The stock options were issued to the Reporting Person on August 17,2023, pursuant to a grant under the Issuer's 2022 Omnibus Incentive Plan, as amended and restated. The award vested in full on August 17, 2023. Read SEC document |
| May 05, 2023 Filed May 17, 2023 23:09 UTC | Inhibitor Therapeutics, Inc. INTI · Entity 7783 | OtherCommon Stock | 796,271 | $0.00 | $0.00 |
DisclosureSEC source: 0000899243-23-013195 · doc4.xml · nonDerivative · entry 1 Yanez Michelle · CIK 0001958023 · Director 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 800,673 F1 · kind: Shares of common stock of Inhibitor Therapeutics, Inc. were distributed to the members of Hedgepath, LLC ("HPLLC"), pro-rata pursuant to their membership interest in HPLLC. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.